Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
8.58
-0.28 (-3.16%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers.
The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma.
It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015.
The company was incorporated in 2015 and is based in Fort Worth, Texas.
Actuate Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Aug 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Daniel Schmitt |
Contact Details
Address: 1751 River Run, Suite 400 Fort Worth, Texas 76107 United States | |
| Phone | 817 887 8455 |
| Website | actuatetherapeutics.com |
Stock Details
| Ticker Symbol | ACTU |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0001652935 |
| Employer ID | 47-3044785 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel M. Schmitt | Chief Executive Officer, President and Director |
| Dr. Andrew P. Mazar Ph.D. | Co-Founder and Chief Operating Officer |
| Dr. Alan Kozikowski Ph.D. | Scientific Founder and Advisor |
| Paul J. Lytle CPA | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Sep 24, 2024 | 10-Q | Quarterly Report |
| Aug 19, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 19, 2024 | 8-K | Current Report |
| Aug 14, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 13, 2024 | POS EX | Filing |
| Aug 13, 2024 | 424B4 | Prospectus |
| Aug 12, 2024 | EFFECT | Notice of Effectiveness |